Roche bets big on hanmi’s obesity drug in pipeline push

Roche CEO Thomas Schinecker underscores the company’s confidence in its robust late-stage pipeline, describing it as so full that there is no current pressure to pursue major acquisitions. This strategic stance is particularly notable given the surge in biopharma acquisitions throughout 2026, during which Roche opted for modest investments and prioritized organic growth by advancing its existing pipeline and diagnostics capabilities rather than chasing large deals.

Looking ahead to 2030, Roche aims to launch up to 19 potential drugs, including high-revenue candidates such as the obesity therapies petrelintide and enicepatide, the Alzheimer’s treatment trontinemab, and the breast cancer drug giredestrant, each projected to exceed $3 billion in peak sales. This ambitious slate of launches complements Roche’s already strong sales momentum in early 2026, driven by established pharmaceuticals like Ocrevus, Hemlibra, and Vabysmo, alongside growth products Xolair and Polivy, collectively reinforcing a robust growth outlook.

In a landmark $2.5 billion global licensing agreement excluding South Korea, Roche’s Genentech unit has acquired rights to Hanmi Pharm’s clinical-stage obesity drug HM17321, paying a $190 million upfront fee with potential milestone payments reaching $2.3 billion. This deal underscores Roche’s strategic ambition to expand beyond its existing obesity portfolio by targeting novel mechanisms that address unmet needs in weight management and cardiometabolic health.

HM17321 distinguishes itself by leveraging a novel, non-incretin UCN2 mechanism designed to promote weight loss while preserving lean body mass, a significant advancement over current GLP-1-based therapies that often compromise muscle mass. Roche plans to develop this candidate not only for obesity but also for related cardiometabolic conditions such as type 2 diabetes and cardiovascular diseases, aligning with its broader goal of becoming a top-tier player in the weight loss and metabolic disease arena.

This licensing deal complements Roche’s existing obesity pipeline, including its own candidate emugrobart, reflecting a deliberate strategy to diversify into differentiated mechanisms that improve body composition rather than simply reducing weight. By integrating HM17321, Roche is positioning itself to challenge the current therapeutic landscape with innovative approaches that could redefine treatment paradigms for obesity and associated metabolic disorders.

Structurally, the agreement mitigates risk for Hanmi with non-refundable upfront payments and no penalties if development fails, while granting Roche a promising asset contingent on successful clinical trials, regulatory approvals, and U.S. antitrust clearance under the HSR Act. This risk-balanced framework enables Roche to invest confidently in HM17321’s potential to disrupt the obesity treatment market while safeguarding Hanmi’s interests.

HM17321 represents a pioneering shift in obesity treatment by employing a unique non-incretin mechanism that targets the corticotropin-releasing factor receptor type 2 (CRF2), setting it apart from established GLP-1 therapies. Unlike these incretin-based drugs, which often lead to undesirable lean body mass loss, HM17321 is designed to simultaneously promote significant weight loss while preserving or even enhancing muscle mass and function. This evolution in therapeutic strategy reflects a broader paradigm shift towards improving overall body composition and metabolic health rather than focusing solely on weight reduction.

Roche’s $2.5 billion licensing deal for HM17321 underscores its strategic commitment to diversifying its cardiometabolic portfolio with innovative, high-value therapies that address unmet needs in obesity treatment. Boris Zaïtra, Head of Roche Corporate Business Development, emphasized the company’s pursuit of a differentiated approach that selectively reduces fat mass while simultaneously improving muscle mass and function, aligning perfectly with Hanmi’s H.O.P. project vision to overcome limitations of existing therapies by preventing muscle loss. This collaboration positions Roche and Genentech at the forefront of next-generation obesity therapeutics.

Preclinical data for HM17321 reveal compelling efficacy and safety advantages over current GLP-1 drugs, including up to 17.5% weight loss and over 40% reduction in body fat, alongside notable improvements in muscle mass, grip strength, and musculoskeletal health. Remarkably, when combined with an amylin-class obesity drug, fat reduction soared to 56.5% without appetite suppression, and muscle gains doubled, highlighting synergistic potential. Additionally, HM17321 demonstrated cardiometabolic benefits such as lowering blood pressure and heart rate, preventing renal decline seen with semaglutide, and improving heart failure markers, further validating its role in Roche’s strategy to develop multifaceted, next-generation cardiometabolic therapies.

Hanmi Pharmaceutical's landmark $2.3 billion global licensing and technology transfer agreement with Genentech for HM17321 underscores the company's long-term dedication and robust R&D capabilities in obesity drug innovation. This deal, featuring a $190 million upfront payment and over $2.1 billion in milestone and royalty payments, not only validates Hanmi's novel approach targeting the CRF2 receptor with a long-acting UCN2 analog but also marks the largest single-asset technology transfer in the company's history, reflecting strong commercial confidence in its obesity pipeline.

HM17321 distinguishes itself from existing GLP-1 therapies by delivering significant therapeutic benefits, including up to 17.5% weight loss, more than 40% reduction in body fat, and improved muscle mass and function, as demonstrated in preclinical studies presented at the ADA annual scientific sessions. This breakthrough mechanism not only addresses obesity but also counters muscle loss, positioning Hanmi's candidate as a next-generation obesity treatment with substantial clinical promise.

Hanmi's strategic pivot toward an obesity-focused portfolio through its H.O.P. (Hanmi Obesity Pipeline) project signals a deliberate expansion into diverse mechanisms and formulations, including cost-effective GLP-1 agents, triple agonists, muscle loss prevention drugs, oral formulations, and digital therapeutics. This comprehensive pipeline not only broadens Hanmi's innovation horizon but also sets the stage for multiple future licensing deals, as evidenced by growing market anticipation for candidates like Efeglenatide and HM15275, thereby reinforcing Hanmi's evolving R&D strategy and industry impact.